Effect of HAART treatment on CD8+ cell noncytotoxic
anti-HIV activity in primary infection. The percentage of suppression
of HIV-1SF33 replication at a
CD8+:CD4+ cell ratio of 0.5:1 is presented for
21 individuals experiencing the primary stages of HIV infection and
receiving highly active antiretroviral therapy for a period of 24
weeks. Week 0 represents the level of CD8+ cell suppression
before the initiation of HAART, compared with weeks 4, 12, or 24 of
treatment. Statistical significance was determined by comparing the
actual suppression values of all participants at week 0 with these same
measurements at week 24 (P = 0.01). Red line,
maintained or enhanced antiviral response; blue line, decreased
antiviral response.